Table 4.
Summary of Kan Jang® (A. paniculata and E. senticosus extracts) treatment outcomes in previous clinical studies.
| First author name | Melchior | Melchior | Gabrielian | Kulichenko | Kulichenko | Spasov | Narimanyan |
|---|---|---|---|---|---|---|---|
| Year | 2000 | 2000 | 2002 | 2003 | 2003 | 2004 | 2012 |
| Diagnosis | URTI | URTI | URTI, sinusitis | Influenza | Influenza | influenza | URTI |
| Type of study | R-PC-DB | R-PC-DB | PC-DB | R-PC-OL pilot | R-PC-OL | R-C-DB | R-PC-DB prospective |
| Number of patients verum/control | 23/23 | 89/90 | 95/90 | 71/469 | 35/31 | 53/41/39 children | 94/85 |
| Negative control | Placebo | Placebo | Placebo | Placebo | Placebo | Placebo | |
| Positive control | Amantadine, paracetamol and vit. C | Amantadine, paracetamol and vit. C | Immunal (Echinacea extract) | ||||
| Daily dose | 12 tablets | 12 Tablets |
12 tablets | 6 tablets | 9 tablets | 6 tablets | 12 capsules |
| Daily dose of andrographolides, mg | 60 | 60 | 60 | 30 | 45 | 30 | 60 |
| Duration of treatment, days | 5 | 5 | 5 | 3–5 | 5 | 10 | 5 |
| Cough | ⓪ | ⓿ | ⓿ | ⓪ | ⓿ dos | ⓪ | ⓿ |
| Sore throat | ⓿ | ⓿ | ⓿ | ⓪ | ⓿ dos | ⓪ | ⓿ |
| Nasal secretion | ⓪ | ⓪ | ⓿ | ⓪ | ⓿ dos | ⓿ | ⓿ |
| Nasal congestions | ⓪ | ⓪ | ⓿ | ⓪ | ⓿ | ⓿ | ⓿ |
| Hoarseness | ⓪ | ⓪ | ⓿ | ⓪ | ⓿ | ⓪ | ⓿ |
| Headache | ⓪ | ⓪ | ⓿ | ⓿ | ⓿ dos | ⓪ | ⓿ |
| Muscle soreness | ⓿ | ⓿ | ⓪ | ⓿ | ⓪ | ||
| Eye discharge | ⓪ | ⓪ | ⓪ | ⓿ | ⓿ dos | ⓪ | |
| Temperature | ⓪ | ⓪ | ⓪ | ⓿ | ⓪ | ⓪ | ⓿ |
| Malaise/fatigue | ⓿ | ⓪ | ⓪ | ⓿ | |||
| Total symptoms | ⓪ | ⓿ | ⓿ | ⓿ | |||
| Duration of sick leave at home, days | ⓿ 7.2 vs. 9.8 |
⓿ 7.2 vs. 9.8 |
⓿ 2.4 vs. 3.0 |
||||
| Number of patients at home, median ratio | ⓿ 1.5 |
||||||
| Post-influenza Complications | ⓿ | ||||||
| Blood hematology | ⓪ | ⓿ | |||||
| IL-8, IgA, IgG | ⓪ |
Statistical significance of differences between Kan Jang® and placebo: ⓪ –p > 0.05, ⓿ –p < 0.05, ⓿ - not assessed.